CEO of Plus Therapeutics Simultaneously Vests RSUs While Off‑Loading Shares: A Sign of Long‑Term Commitment Amid Market Decline

Insider Activity at Plus Therapeutics: What It Means for Investors

The latest insider filing from CEO Marc H. HEDRICK shows a complex set of transactions that combine the vesting of RSUs with a subsequent sell‑off of common stock and the sale of the underlying restricted units. On April 1, 2026, he added 159,681 shares to his holdings through the vesting of a quarterly RSU grant, simultaneously selling 201,632 shares of common stock and the corresponding 201,632 restricted units. This pattern—adding shares via vesting while off‑loading the same amount through sales—suggests a strategy of maintaining a stable equity stake while liquidating the proceeds for cash flow or diversification.

From an investor’s perspective, the timing of these trades is noteworthy. The company’s share price is currently trading at roughly $0.16, a steep decline of nearly 79 % year‑to‑date. The CEO’s decision to sell shares in the middle of a bear market may raise questions about confidence in near‑term upside. However, the simultaneous RSU vesting indicates that the executive remains committed to the long‑term success of the business, as the vested units will only become fully exercisable over the next 12 months.

Broader Insider Trend

Other senior executives have shown similar activity. CFO Andrew MacIntyre has executed four buy‑transactions on the same day, adding significant common stock and restricted units to his portfolio. Across the board, insider purchases have increased in the past year, reflecting a broader trend of executives betting on the company’s pipeline. This duality—executives buying while also selling—points to a pragmatic approach: they are willing to fund liquidity needs or personal diversification while still locking in future upside through RSUs and options.

CEO Marc H. HEDRICK: A Transaction Profile

Examining HEDRICK’s historical filings reveals a pattern of aggressive grant purchases. In February 2026, he bought 2.42 million stock options and an equal amount of restricted units, increasing his holdings to over 4 million shares. Earlier, in August 2025, he added more than 1.9 million restricted units and 5.7 million options, bringing his total to roughly 5.8 million shares. These large‑volume transactions show a willingness to take on significant dilution in exchange for future upside—an approach that aligns with the company’s aggressive clinical development agenda.

Moreover, his RSU transactions are structured as quarterly vesting over 12 months, a common incentive design that encourages long‑term focus. The recent sell of both common shares and the corresponding restricted units may be a tactical move to realize gains before the next vesting cycle while preserving his vested stake for future growth.

Implications for the Company’s Future

For Plus Therapeutics, the CEO’s activity signals that executive confidence remains intact, despite a volatile share price and a challenging biopharma landscape. The company’s focus on advancing its lead product, REYOBIQ, and expanding its diagnostics platform suggests that the business has tangible milestones ahead. The insider buys in the last quarter of 2025 and the continued RSU grants imply a belief that the company’s valuation will rebound as clinical data materializes.

Nonetheless, the CEO’s recent share sales during a period of steep decline may raise concerns about liquidity or personal cash needs. Investors should monitor whether these sales are a one‑off event or part of a broader pattern that could indicate a shift in executive sentiment. As the company approaches its upcoming annual meeting, the governance proposals and stock‑incentive plan changes will also be scrutinized for how they align executive incentives with shareholder value.

Takeaway for Investors

• Stability Amid Volatility: HEDRICK’s RSU vesting indicates a long‑term commitment, while the share sales provide liquidity.
• Executive Confidence: Large purchases of options and restricted units in the past year reflect confidence in the pipeline.
• Watch for Future Moves: Continued insider buys or sells, especially in the context of upcoming regulatory milestones, could be a signal of evolving sentiment.
• Strategic Focus: The company’s clinical pipeline and governance updates suggest a firm roadmap, but the market’s negative sentiment remains a risk factor.

By keeping an eye on these insider dynamics, investors can better gauge the alignment of executive incentives with the company’s long‑term prospects.